Mirum Pharmaceuticals, Inc. Investing Cash Flow
Mirum Pharmaceuticals, Inc. (MIRM) reported Investing Cash Flow of -$171.56 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-05
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$159.99M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$11.57M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $1.01M, a 56.94% increase year-over-year.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$2.23M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$23.95M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$90.13M.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$107.20M, a 1492.21% decline from fiscal 2022.
- Mirum Pharmaceuticals, Inc. net cash provided by (used in) investing activities for fiscal 2022 was $7.70M, a 84.14% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 3 month as first filed | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 8 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$159.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$171.56M 10-Q · filed 2026-08-05 | -$170.55M derived: sum of 3 quarters · filed 2026-08-05 | -$172.78M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | -$11.57M 10-Q · filed 2026-05-06 | -$10.56M derived: sum of 2 quarters · filed 2026-05-06 | -$12.79M derived: sum of 3 quarters · filed 2026-05-06 | -$19.39M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$1.22M derived: sum of 2 quarters · filed 2026-02-25 | -$7.82M derived: sum of 3 quarters · filed 2026-08-05 | -$23.95M 10-K · filed 2026-02-25 | ||
| 2025-09-30 | -$2.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$8.83M derived: sum of 2 quarters · filed 2026-08-05 | -$24.96M 10-Q · filed 2025-11-04 | -$24.32M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-06-30 | -$6.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$22.73M 10-Q · filed 2026-08-05 | -$22.09M derived: sum of 3 quarters · filed 2026-08-05 | -$40.13M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-03-31 | -$16.13M 10-Q · filed 2026-05-06 | -$15.49M derived: sum of 2 quarters · filed 2026-05-06 | -$33.53M derived: sum of 3 quarters · filed 2026-05-06 | -$106.25M derived: sum of 4 quarters · filed 2026-05-06 | ||
| 2024-12-31 | $641.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$17.39M derived: sum of 2 quarters · filed 2026-02-25 | -$90.11M derived: sum of 3 quarters · filed 2026-02-25 | -$90.13M 10-K · filed 2026-02-25 | ||
| 2024-09-30 | -$18.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$90.75M derived: sum of 2 quarters · filed 2025-11-04 | -$90.77M 10-Q · filed 2025-11-04 | -$92.77M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-06-30 | -$72.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$72.73M 10-Q · filed 2025-08-06 | -$74.73M derived: sum of 3 quarters · filed 2026-02-25 | -$257.49M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2024-03-31 | -$13.00K 10-Q · filed 2025-05-07 | -$2.01M derived: sum of 2 quarters · filed 2026-02-25 | -$184.78M derived: sum of 3 quarters · filed 2026-02-25 | -$134.23M derived: sum of 4 quarters · filed 2026-02-25 | ||
| 2023-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$184.76M derived: sum of 2 quarters · filed 2026-02-25 | -$134.22M derived: sum of 3 quarters · filed 2026-02-25 | -$107.20M 10-K · filed 2026-02-25 | ||
| 2023-09-30 | -$182.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$132.22M derived: sum of 2 quarters · filed 2024-11-12 | -$105.20M 10-Q · filed 2024-11-12 | -$78.44M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-06-30 | $50.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $77.56M 10-Q · filed 2024-08-07 | $104.32M derived: sum of 3 quarters · filed 2025-02-26 | $24.79M derived: sum of 4 quarters · filed 2025-02-26 | ||
| 2023-03-31 | $27.02M 10-Q · filed 2024-05-08 | $42.02M 10-Q · filed 2023-05-04 | $53.77M derived: sum of 2 quarters · filed 2025-02-26 | -$25.76M derived: sum of 3 quarters · filed 2025-02-26 | -$1.78M derived: sum of 4 quarters · filed 2025-02-26 | |
| 2022-12-31 | $26.76M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$52.77M derived: sum of 2 quarters · filed 2025-02-26 | -$28.80M derived: sum of 3 quarters · filed 2025-02-26 | $7.70M 10-K · filed 2025-02-26 | ||
| 2022-09-30 | -$79.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$55.56M derived: sum of 2 quarters · filed 2023-11-02 | -$19.06M 10-Q · filed 2023-11-02 | $88.97M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-06-30 | $23.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $60.47M 10-Q · filed 2023-08-07 | $168.49M derived: sum of 3 quarters · filed 2024-03-15 | $166.26M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2022-03-31 | $36.50M 10-Q · filed 2023-05-04 | $144.52M derived: sum of 2 quarters · filed 2024-03-15 | $142.29M derived: sum of 3 quarters · filed 2024-03-15 | $117.83M derived: sum of 4 quarters · filed 2024-03-15 | ||
| 2021-12-31 | $108.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $105.79M derived: sum of 2 quarters · filed 2024-03-15 | $81.33M derived: sum of 3 quarters · filed 2024-03-15 | $48.55M 10-K · filed 2024-03-15 | ||
| 2021-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$26.69M derived: sum of 2 quarters · filed 2022-11-09 | -$59.48M 10-Q · filed 2022-11-09 | -$64.42M derived: sum of 4 quarters · filed 2022-11-09 | ||
| 2021-06-30 | -$24.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$57.24M 10-Q · filed 2022-08-04 | -$62.19M derived: sum of 3 quarters · filed 2022-08-04 | -$81.10M derived: sum of 4 quarters · filed 2022-08-04 | ||
| 2021-03-31 | -$32.78M 10-Q · filed 2022-05-05 | -$37.73M derived: sum of 2 quarters · filed 2022-05-05 | -$56.64M derived: sum of 3 quarters · filed 2022-05-05 | -$28.67M derived: sum of 4 quarters · filed 2022-05-05 | ||
| 2020-12-31 | -$4.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-09 | -$23.86M derived: sum of 2 quarters · filed 2022-03-09 | $4.11M derived: sum of 3 quarters · filed 2022-03-09 | $37.87M 10-K · filed 2022-03-09 | ||
| 2020-09-30 | -$18.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $9.06M derived: sum of 2 quarters · filed 2021-11-15 | $42.82M 10-Q · filed 2021-11-15 | $37.68M derived: sum of 4 quarters · filed 2021-11-15 | ||
| 2020-06-30 | $27.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $61.73M 10-Q · filed 2021-08-05 | $56.59M derived: sum of 3 quarters · filed 2021-08-05 | -$7.60M derived: sum of 4 quarters · filed 2021-08-05 | ||
| 2020-03-31 | $33.76M 10-Q · filed 2021-05-06 | $28.62M derived: sum of 2 quarters · filed 2021-05-06 | -$35.58M derived: sum of 3 quarters · filed 2021-05-06 | -$93.98M derived: sum of 4 quarters · filed 2021-05-06 | ||
| 2019-12-31 | -$5.14M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | -$69.34M derived: sum of 2 quarters · filed 2021-03-09 | -$127.74M derived: sum of 3 quarters · filed 2021-03-09 | -$127.78M 10-K · filed 2021-03-09 | ||
| 2019-09-30 | -$64.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$122.59M derived: sum of 2 quarters · filed 2020-11-12 | -$122.64M 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | -$58.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$58.45M 10-Q · filed 2020-08-06 | ||||
| 2019-03-31 | -$44.00K 10-Q · filed 2020-05-07 | |||||
| 2018-12-31 | -$7.50M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |